MedTrace Logo

Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL)

NCT03188874 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 15000

Last updated 2026-04-21

No results posted yet for this study

Summary

This is a registry study in adult patients with newly diagnosed or refractory/relapsed acute myeloid leukemia.

Investigator's sites: 60 sites in Germany.

Primary objectives:

* Identification of epidemiological data on AML: age, prognostic factors and subgroup distributions. Incidence and age distribution are compared with the data of population-related tumor registry.
* Evaluation of the most important patient-relevant clinical endpoints (outcomes): relapse-free survival (RFS) / time to relapse (TTR), calculation of cumulative incidence of relapse (CIR) and overall survival (OS)
* Documentation of treatment strategy

Conditions

  • Acute Myeloid Leukemia (AML)

Sponsors & Collaborators

  • Technische Universität Dresden

    lead OTHER

Principal Investigators

  • Christoph Röllig, Prof. Dr. · Universitätsklinikum Carl Gustav Carus

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2030-09-30
Completion
2030-09-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03188874 on ClinicalTrials.gov